Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Tian, Wentao;Ning, Jiaoyang;Chen, Liu;Zeng, Yu;Shi, Yin;...

通讯作者：

Tanzhu, Guilong;Zhou, RR

作者机构：

[Ning, Jiaoyang; Zhou, Rongrong; Xiao, Gang; Tanzhu, Guilong; Zhou, RR; Tian, Wentao; Chen, Liu; Tanzhu, G] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Peoples R China.

[Zeng, Yu] Hunan Univ Tradit Chinese Med, Changsha Stomatol Hosp, Changsha, Peoples R China.

[Shi, Yin] Xiangya Hosp, Dept Pharm, Changsha, Peoples R China.

[He, Shuangshuang] Sichuan Univ, West China Hosp, Canc Ctr, Dept Radiat Oncol, Chengdu, Sichuan, Peoples R China.

[He, Shuangshuang] Sichuan Univ, West China Hosp, Canc Ctr, Dept Head & Neck Oncol, Chengdu, Sichuan, Peoples R China.

通讯机构：

[Zhou, RR ; Tanzhu, G] C

Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Peoples R China.

语种：

英文

关键词：

advanced non-small cell lung cancer;chemotherapy;cost-effectiveness;immunotherapy;tumor treating fields

期刊：

Frontiers in Pharmacology

ISSN：

1663-9812

年：

2024

卷：

页码：

1333128

DOI：

10.3389/fphar.2024.1333128

基金类别：

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Multidisciplinary Cooperative Diagnosis and Treatment Capacity (lung cancer z027002), National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University (No. 2022LNJJ10), Advanced Lung Cancer Targeted Therapy Research Foundation of China (CTONG-YC20210303), and Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province (CXPJJH121005-01).

机构署名：

本校为其他机构

摘要：

Background: Tumor treating fields (TTF) was first approved for treatment of glioblastoma. Recently, the LUNAR study demonstrated that TTF + standard therapy (ST) extended survival in patients with advanced non-small cell lung cancer (NSCLC). This primary objective of this study is to analyze the cost-effectiveness of this treatment from the United States healthcare payers' perspective. Methods: A 3-health-state Markov model was established to compare the cost-effectiveness of TTF + ST and that of ST alone. Clinical data were extracted from the LUNAR study, supplemented by additional cost and u...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问